Charlotte's Web narrows Q3 operating loss as California hemp limits cut revenue 18%
The US CBD maker reports its smallest operating loss since 2019 and warns that a federal hemp restriction taking effect on 11 December could cover its full-spectrum products.
Charlotte's Web Holdings reported results for the quarter ended 30 September 2026 on 12 November. Revenue fell to $9.4m from $11.5m a year earlier, a decline of about 18%. The company attributed the fall mainly to California's limits on full-spectrum hemp sales, together with reduced discounting.
The operating loss narrowed to $3.7m, which the company's own headline describes as the lowest since 2019.
Looking ahead, the company flagged a federal hemp restriction, referred to as Section 781, which is due to take effect on 11 December 2026 unless Congress amends it. The company says the measure would cover its full-spectrum CBD products.
Charlotte's Web also said it is negotiating with accountable care organisations (ACOs) on a CMS pilot, referred to as BEI, which is expected in 2027. It noted progress on AJA001, a drug candidate being developed by DeFloria. No further detail on either was available in the information provided.
Why it matters
- Regulatory teams with hemp-derived or CBD products in the US should track whether Congress amends Section 781 before the 11 December 2026 effective date, as full-spectrum products are in scope according to the company.
- California's limits on full-spectrum hemp sales are already visible in a manufacturer's revenue, a sign that state-level rules can affect sales alongside federal action.
- Market-access teams may want to watch the CMS pilot and the ACO negotiations, expected in 2027, for any reimbursement or channel implications.
Company's press release (SEC filing): Charlotte's Web Holdings, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
